Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

141. Asthma

Asthma Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading

2018 Trip Evidence Maps

142. Combined Analysis of Asthma Safety Trials of Long-Acting β<sub>2</sub>-Agonists. Full Text available with Trip Pro

Combined Analysis of Asthma Safety Trials of Long-Acting β2-Agonists. Safety concerns regarding long-acting β2-agonists (LABAs) in asthma management were initially identified in a large postmarketing trial in which the risk of death was increased. In 2010, the Food and Drug Administration (FDA) mandated that the four companies marketing LABAs for asthma perform prospective, randomized, controlled trials comparing the safety of combination therapy with a LABA plus an inhaled (...) outcome was a composite of asthma-related intubation or death. Post hoc secondary outcomes included serious asthma-related events and asthma exacerbations.Among the 36,010 patients in the intention-to-treat study, there were three asthma-related intubations (two in the inhaled-glucocorticoid group and one in the combination-therapy group) and two asthma-related deaths (both in the combination-therapy group) in 4 patients. In the secondary analysis of serious asthma-related events (a composite

2018 NEJM

143. Prevalence and Risk Factors of Asthma and Allergy-Related Diseases among Adolescents (PERFORMANCE) study: rationale and methods Full Text available with Trip Pro

Prevalence and Risk Factors of Asthma and Allergy-Related Diseases among Adolescents (PERFORMANCE) study: rationale and methods Despite a considerable number of international reports on allergic diseases among children, information about the prevalence and risk factors of asthma and allergy-related diseases among Indian adolescents is relatively sparse. The Prevalence and Risk Factors of Asthma and Allergy-Related Diseases among Adolescents (PERFORMANCE) study has been conceived to study (...) the aetiology of asthma and allergic diseases including rhinoconjunctivitis, atopic eczema and food allergies among adolescents in West Bengal, India, using standardised methods and collaborations. The aims of the study are: 1) to estimate the prevalence and risk factors of asthma and allergic diseases among the adolescents residing in rural, suburban and urban areas of West Bengal; 2) to obtain information about the possible role of lifestyle factors (smoking, diet and physical activity) on the disease

2018 ERJ open research

144. Prevalence of asthma among male 16 to 18-year-old adolescents in the Northern Borders Region of Saudi Arabia Full Text available with Trip Pro

version 20, using descriptive statistics and Chi-square test. A p-value of 0.05 or less was considered, statistically significant.Among the 511 students, the prevalence of physician-diagnosed asthma was 11.4%. The prevalence of lifetime wheeze, and exercise-induced wheeze were 30.3% and 19% respectively. The prevalence of night cough and wheezing attack in the past 12 months were 17% and 16.8% respectively. A total of 51.8% of asthmatic students have poor asthma control.The prevalence of asthma (...) and associated symptoms in 16 to18-year-old students is high in the Northern Borders Region. Uncontrolled asthma was observed in half of asthmatic students.

2018 Electronic physician

145. Fluticasone/formoterol (flutiform k-haler) - for the regular treatment of asthma

Fluticasone/formoterol (flutiform k-haler) - for the regular treatment of asthma Abbreviated Submission fluticasone propionate/ formoterol fumarate 50microgram/5microgram, 125microgram/5microgram pressurised inhalation, suspension (Flutiform k-haler ® ) SMC2016 Napp Pharmaceuticals Ltd 4 May 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission fluticasone propionate/ formoterol fumarate (Flutiform k-haler ® ) is accepted for use within NHS Scotland. Indication under review: for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting ß 2-agonist (LABA)] is appropriate: • For patients not adequately controlled with ICS as ‘as required’ inhaled short-acting ß2- agonist or • For patients already adequately controlled

2018 Scottish Medicines Consortium

146. Evaluation of catgut implantation at acupoints for asthma: A systematic review and meta-analysis Full Text available with Trip Pro

in adult-onset asthma: 12-Year follow-up study . Respir Med 2018 ; 137 (1) :70–6. , 10. Li J, Zhang F, Li J . The immunoregulatory effects of traditional Chinese medicine on treatment of asthma or asthmatic inflammation . Am J Chin Med 2015 ; 43 (6) :1059–81. , 11. Ma YC, Lin CC, Li CI et al. , Time-trend analysis of prevalence, incidence and traditional Chinese medicine use among children with asthma: A population-based study . J Public Health 2016 ; 38 (3) :e263–71. , 12. Wang N, Li J, Huang X et al (...) . , Herbal medicine Cordyceps sinensis improves health-related quality of life in moderate-to-severe asthma . Evid Based Complement Alternat Med 2016 ; 2016 :6134593. , 13. Yin LM, Jiang GH, Wang Y et al. , Use of serial analysis of gene expression to reveal the specific regulation of gene expression profile in asthmatic rats treated by acupuncture . J Biomed Sci 2009 ; 16 :46. , 14. Wei Y, Dong M, Zhang H et al. , Acupuncture attenuated inflammation and inhibited Th17 and treg activity in experimental

2018 Traditional Medicine and Modern Medicine

147. Entropy Change of Biological Dynamics in Asthmatic Patients and Its Diagnostic Value in Individualized Treatment: A Systematic Review Full Text available with Trip Pro

physiological data collected from monitoring devices is being studied from different perspectives. Entropy, as an analysis method for quantifying the inner irregularity of data, has been widely applied in physiological signals. However, based on our knowledge, there is no such study to summarize the complexity differences of various physiological signals in asthmatic patients. Therefore, we organized a systematic review to summarize the complexity differences of important signals in patients with asthma. We (...) Entropy Change of Biological Dynamics in Asthmatic Patients and Its Diagnostic Value in Individualized Treatment: A Systematic Review Entropy | Free Full-Text | Entropy Change of Biological Dynamics in Asthmatic Patients and Its Diagnostic Value in Individualized Treatment: A Systematic Review Next Article in Journal Next Article in Special Issue Previous Article in Journal Previous Article in Special Issue Information Initiatives Notice You can make submissions to other journals . You seem

2018 Entropy

148. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. Full Text available with Trip Pro

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and safety in patients with uncontrolled asthma.We randomly assigned 1902 patients 12 years of age or older with uncontrolled asthma in a 2:2:1:1 ratio to receive add-on subcutaneous dupilumab at a dose of 200 or 300 mg every 2 weeks or matched-volume placebos (...) for 52 weeks. The primary end points were the annualized rate of severe asthma exacerbations and the absolute change from baseline to week 12 in the forced expiratory volume in 1 second (FEV1) before bronchodilator use in the overall trial population. Secondary end points included the exacerbation rate and FEV1 in patients with a blood eosinophil count of 300 or more per cubic millimeter. Asthma control and dupilumab safety were also assessed.The annualized rate of severe asthma exacerbations

2018 NEJM Controlled trial quality: predicted high

149. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. Full Text available with Trip Pro

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral glucocorticoid use in patients with severe asthma while maintaining asthma control is unknown.We randomly assigned 210 patients with oral glucocorticoid-treated asthma to receive add-on dupilumab (at a dose of 300 mg) or placebo every 2 weeks for 24 (...) with glucocorticoid-dependent severe asthma, dupilumab treatment reduced oral glucocorticoid use while decreasing the rate of severe exacerbations and increasing the FEV1. Transient eosinophilia was observed in approximately 1 in 7 dupilumab-treated patients. (Funded by Sanofi and Regeneron Pharmaceuticals; LIBERTY ASTHMA VENTURE ClinicalTrials.gov number, NCT02528214 .).

2018 NEJM Controlled trial quality: predicted high

150. Dynamic hyperinflation during the 6-min walk test in severely asthmatic subjects Full Text available with Trip Pro

=0.32) and decreased in both groups (mean difference: for asthmatic subjects 0.160 L; p=0.02; for COPD subjects 0.164 L; p<0.0001). However, changes in IC were significantly associated with changes in the Borg score in the COPD group (r2=0.17; p=0.006), but not in the asthma group (r2=0.06; p=0.20). In severe asthmatic subjects, IC significantly drops during the 6MWT to the same extent as COPD subjects with a similar degree of lung impairment, indicating the development of dynamic hyperinflation (...) Dynamic hyperinflation during the 6-min walk test in severely asthmatic subjects We tested the hypothesis that dynamic hyperinflation develops in severe asthmatic subjects during exercise. Changes in inspiratory capacity (IC) were measured during the 6-min walk test (6MWT) in severe asthmatic subjects compared with chronic obstructive pulmonary disease (COPD) subjects with a similar degree of bronchial obstruction. We assessed whether changes in IC were associated with changes in dyspnoea

2018 ERJ open research

151. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. (Abstract)

As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. Patients with mild asthma often rely on inhaled short-acting β2-agonists for symptom relief and have poor adherence to maintenance therapy. Another approach might be for patients to receive a fast-acting reliever plus an inhaled glucocorticoid component on an as-needed basis to address symptoms and exacerbation risk.We conducted a 52-week, double-blind, multicenter trial involving patients 12 years of age or older who (...) had mild asthma and were eligible for treatment with regular inhaled glucocorticoids. Patients were randomly assigned to receive twice-daily placebo plus budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed or budesonide maintenance therapy with twice-daily budesonide (200 μg) plus terbutaline (0.5 mg) used as needed. The primary analysis compared budesonide-formoterol used as needed with budesonide maintenance therapy with regard to the annualized rate of severe

2018 NEJM Controlled trial quality: predicted high

152. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. (Abstract)

Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β2-agonist may be an alternative to conventional treatment strategies.We conducted a 52-week, double-blind trial involving patients 12 years of age or older with mild asthma. Patients were randomly assigned to one of three regimens: twice-daily placebo plus terbutaline (0.5 mg) used as needed (terbutaline group), twice-daily placebo plus (...) in the budesonide-formoterol group, and 1282 in the budesonide maintenance group) were included in the full analysis and safety data sets. With respect to the mean percentage of weeks with well-controlled asthma per patient, budesonide-formoterol was superior to terbutaline (34.4% vs. 31.1% of weeks; odds ratio, 1.14; 95% confidence interval [CI], 1.00 to 1.30; P=0.046) but inferior to budesonide maintenance therapy (34.4% and 44.4%, respectively; odds ratio, 0.64; 95% CI, 0.57 to 0.73). The annual rate

2018 NEJM

153. Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma

Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma Comparative Effectiveness Review Number 194 Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma e Comparative Effectiveness Review Number 194 Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 (...) of intermittent inhaled corticosteroids in different populations of patients with asthma and to assess whether adding long-acting muscarinic antagonists improves outcomes for patients with uncontrolled, persistent asthma. Key Messages • In children less than 5 years old with recurrent wheezing, intermittent use of inhaled corticosteroids during an upper respiratory tract infection decreases asthma exacerbations • In patients 12 years and older with persistent asthma: o using inhaled corticosteroids

2018 Effective Health Care Program (AHRQ)

154. Role of Immunotherapy in the Treatment of Asthma

of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy. 2005 Sep;60(9):1178- 83. doi: 10.1111/j.1398-9995.2005.00862.x. PMID: 16076305. 8. Olsen OT, Larsen KR, Jacobsan L, et al. A 1- year, placebo-controlled, double-blind house- dust-mite immunotherapy study in asthmatic adults. Allergy. 1997 Aug;52(8):853-9. PMID: 9284985. 9. Baris S, Kiykim A, Ozen A, et al. Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust (...) immunotherapy efficacy in children with house dust mite- induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol. 2007 Feb;18(1):47-57. doi: 10.1111/j.1399- 3038.2006.00475.x. PMID: 17295799. 34. Lue KH, Lin YH, Sun HL, et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo- controlled study. Pediatr Allergy Immunol. 2006 Sep;17(6):408-15. doi

2018 Effective Health Care Program (AHRQ)

155. A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma (Abstract)

A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma Whether itraconazole monotherapy is effective in the acute stage of allergic bronchopulmonary aspergillosis (ABPA) remains unknown. The goal of this study was to compare the efficacy and safety of itraconazole and prednisolone monotherapy in ABPA.Treatment-naive subjects with ABPA complicating asthma (January 2012 to December 2013) were randomized to receive either oral

2018 EvidenceUpdates

156. Systematic Reviews on Pharmacological Treatment of Asthma and Chronic Obstructive Pulmonary Disease Full Text available with Trip Pro

Systematic Reviews on Pharmacological Treatment of Asthma and Chronic Obstructive Pulmonary Disease Systematic Reviews on Pharmacological Treatment of Asthma and Chronic Obstructive Pulmonary Disease | BRN Reviews OPEN ACCESS Toggle navigation ISSN: 2462-3172 e-ISSN: 2385-7110 ABSTRACT Systematic Reviews on Pharmacological Treatment of Asthma and Chronic Obstructive Pulmonary Disease (doi: ) Gustavo J. Rodrigo , Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo (...) a high level of evidence on the effectiveness of healthcare interventions. Thus, the aim of this article is to provide the most updated information on pharmacological treatment of the two most prevalent chronic obstructive airway diseases, bronchial asthma and chronic obstructive pulmonary disease (COPD), from fourteen SRs of randomized controlled trials (RCTs). This review analyses the strengths and weaknesses of each SR in order to evaluate its clinical applicability. Keywords: Asthma. Chronic

2018 Barcelona Respiratory Network

157. 1086 The association between occupational asthma and skin sensitisation to low-molecular weight agents: a systematic review Full Text available with Trip Pro

1086 The association between occupational asthma and skin sensitisation to low-molecular weight agents: a systematic review 1086 The association between occupational asthma and skin sensitisation to low-molecular weight agents: a systematic review | Occupational & Environmental Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here 1086 The association between occupational asthma and skin sensitisation to low-molecular weight agents: a systematic review Article Text Respiratory Disorders 1086 The association between occupational asthma and skin sensitisation to low-molecular weight agents: a systematic review Free Hung-Chang Tsui , Laurens De Sadeleer , Jeroen Vanoirbeek

2018 Respiratory Disorders

158. Anti-inflammatory and endothelium protective effect of long-term pioglitazone intake in patients suffering from bronchial asthma concurrent with ischemic heart disease. (Abstract)

Anti-inflammatory and endothelium protective effect of long-term pioglitazone intake in patients suffering from bronchial asthma concurrent with ischemic heart disease. Treatment of co-morbidities, including bronchial asthma (BA) and coronary heart disease (CHD), is a relevant issue of modern therapy. The aim of the research is to study the impact of long-term intake of pioglitazone on the development of inflammation and ED in patients with BA concurrent with CHD.The clinical study involved 50 (...) people aged 40-75 who suffered from asthma concurrent with CHD. On the first day of the study, blood samples were collected and clinical examinations were performed, after which patients were randomized and divided into the control group who continued to receive only the standard therapy, and the study group, who received pioglitazone (Pioglar, Ranbaxy, India) 15 mg once a day along with comprehensive therapy. Re-examination was carried out in 6 months.It has been found that inclusion of pioglitazone

2018 Wiadomosci lekarskie (Warsaw, Poland : 1960) Controlled trial quality: uncertain

159. An algorithmic approach for the treatment of severe uncontrolled asthma Full Text available with Trip Pro

An algorithmic approach for the treatment of severe uncontrolled asthma A small subgroup of patients with asthma suffers from severe disease that is either partially controlled or uncontrolled despite intensive, guideline-based treatment. These patients have significantly impaired quality of life and although they constitute <5% of all asthma patients, they are responsible for more than half of asthma-related healthcare costs. Here, we review a definition for severe asthma and present all (...) therapeutic options currently available for these severe asthma patients. Moreover, we suggest a specific algorithmic treatment approach for the management of severe, difficult-to-treat asthma based on specific phenotype characteristics and biomarkers. The diagnosis and management of severe asthma requires specialised experience, time and effort to comprehend the needs and expectations of each individual patient and incorporate those as well as his/her specific phenotype characteristics

2018 ERJ open research

160. Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations. Full Text available with Trip Pro

Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations. Asthma exacerbations occur frequently despite the regular use of asthma-controller therapies, such as inhaled glucocorticoids. Clinicians commonly increase the doses of inhaled glucocorticoids at early signs of loss of asthma control. However, data on the safety and efficacy of this strategy in children are limited.We studied 254 children, 5 to 11 years of age, who had mild-to-moderate persistent asthma and had had (...) at least one asthma exacerbation treated with systemic glucocorticoids in the previous year. Children were treated for 48 weeks with maintenance low-dose inhaled glucocorticoids (fluticasone propionate at a dose of 44 μg per inhalation, two inhalations twice daily) and were randomly assigned to either continue the same dose (low-dose group) or use a quintupled dose (high-dose group; fluticasone at a dose of 220 μg per inhalation, two inhalations twice daily) for 7 days at the early signs of loss

2018 NEJM Controlled trial quality: predicted high